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ABSTRACT: This work presents the design, fabrication, and
characterization of a robust 3D printed microﬂuidic analysis
system that integrates with FDA-approved clinical micro-
dialysis probes for continuous monitoring of human tissue
metabolite levels. The microﬂuidic device incorporates
removable needle type integrated biosensors for glucose and
lactate, which are optimized for high tissue concentrations,
housed in novel 3D printed electrode holders. A soft
compressible 3D printed elastomer at the base of the holder
ensures a good seal with the microﬂuidic chip. Optimization of the channel size signiﬁcantly improves the response time of the
sensor. As a proof-of-concept study, our microﬂuidic device was coupled to lab-built wireless potentiostats and used to monitor
real-time subcutaneous glucose and lactate levels in cyclists undergoing a training regime.
Wearable sensors connected to body sensor networks(BSN)1 that provide real-time information about the
wearer’s health and ﬁtness2 are of great interest both
academically and commercially. Developments of such plat-
forms have mainly focused on sensors that measure physical
vital signs (e.g. pulse rate, ECG). Biosensors targeting
physiologically relevant analytes are more challenging but can
provide important information about tissue health3 and
ﬁtness,4,5 allowing, for example, athletes to tailor their training
to their individual characteristics, enabling them to assess their
training eﬀectiveness, to make adjustments, and to track
improvements in their performance.
Extensive research eﬀorts have focused on the development
of miniaturized on-body chemo/biosensors for the measure-
ment of physiological analytes in diﬀerent bodily ﬂuids, such as
interstitial ﬂuid,6,7 sweat,8,9 tears,10,11 and saliva.12,13 Glucose
and lactate are particularly attractive biomarkers to monitor as
they provide information about tissue energy metabolism.
Lactate, in particular, has received much interest for sports
monitoring. During intense exercise, tissue oxygen levels are
insuﬃcient for aerobic metabolism to meet the energy demands
of the body. Instead, anaerobic metabolism occurs to meet
these increased energy demands, leading to elevated lactate
levels. Lactate can therefore be used as a measure of how hard
the body is working, allowing athletes to modulate their eﬀort
accordingly, in order to train the body to increase its eﬃciency
in clearing excess lactate or to avoid causing damage by
overtraining.
Commercially available blood lactate and glucose meters are
used for sports applications.14 Although blood measurements
provide important information about global metabolite levels in
the body, the use of ﬁnger-prick test strips has several
limitations. The main limitation of discrete sampling is the
lack of temporal resolution, with the result that it is not possible
to observe dynamic changes in metabolite levels. In order to
improve temporal resolution blood samples have to be taken
regularly, resulting in constant interruptions during the activity
period. In contrast, online microdialysis allows continuous
monitoring of tissue metabolites, which, when coupled with an
online analysis system, provides good temporal resolution,
suitable for resolving dynamic changes.15−17 The microdialysis
probe consists of a semipermeable membrane that is perfused
with a solution that matches the extracellular ﬂuid. Formation
of a concentration gradient across the membrane allows
exchange of molecules between the probe and the tissue,
creating a dialysate stream that can be analyzed for compounds
of interest. Microdialysis has been used in a wide range of
applications and is an attractive technology for human in vivo
monitoring, as commercial FDA-approved probes are available.
Microdialysis combined with online analysis systems has been
used extensively to detect tissue health and ischemic
events.18−21 In particular, the lactate/glucose ratio has been
shown to be an especially sensitive marker of tissue health,
providing a clear indication as to whether tissue energy
demands are being met.16,19,22
There is a natural synergy between microdialysis and
microﬂuidic devices because high time resolution analysis of
low volume ﬂow rates requires very small internal
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volumes.17,20,23 Conventionally, microﬂuidic devices have been
made using methods such as PDMS-based soft lithography due
to their ease of fabrication. PDMS chips have been used
extensively for proof-of-concept analysis devices for mass
spectrometry,24 as well as for optical23,25 and electrochemical
detection.20,26,27 In all cases the analyzer is a large device placed
on a bench near the experimental subject. In our current
PDMS-needle biosensor system this requires >1 m of
connection tubing between the probe and the PDMS chip,
leading to a 25 min delay before analysis at 1 μL/min ﬂow rate,
as well as a broadened temporal response due to Taylor
dispersion.28 Furthermore, our current method for manually
positioning the needle electrode biosensors inside the PDMS
chamber is impractical for a wearable device as movement
caused by exercise leads to repositioning of the biosensor inside
the microﬂuidic channel leading to noise and decreased
sensitivity.27
Fast responding wearable devices need to be small and
robust and placed close to the microdialysis probe outlet.29 For
reliability, they require a robust low-volume connection to the
probe and should ideally incorporate biosensors as easily
replaceable modules, given the possibility of biosensor failure
during high-value monitoring of athletes.
Recently, there has been great interest in the use of 3D
printing for the fabrication of microﬂuidic devices.30−34 This
rapid prototyping methodology is particularly attractive as it
enables one-step fabrication of a microﬂuidic platform.35 It also
enables dimensional control of the device, so that it can be
integrated with commercially available components.30 The
versatility of this fabrication method allows for a ﬂexible,
modular-approach to device design with each part designed to
meet exact requirements. It also allows for design modiﬁcations
to be made quickly and easily so that device features can be
adjusted iteratively, and their inﬂuence on the device
performance can be evaluated.30,35 Erkal et al. recently reported
on the fabrication of 3D printed microﬂuidic devices with
integrated electrodes for electrochemical detection.30 These
devices were fabricated using commercial ﬂangeless ﬁtting nuts
to house the electrodes, which integrated with microfabricated
receiving ports.
Here, we show for the ﬁrst time, the development of a 3D
printed microﬂuidic device that integrates with FDA-approved
clinical microdialysis probes and incorporates needle type
biosensors and which can be used for continuous monitoring of
human tissue metabolite levels. As a proof-of-concept, the
device is employed for online monitoring of lactate and glucose
tissue levels during cycling trials, providing a robust and reliable
platform with potential use for wearable sensing technologies.
Figure 1. A. Standard microdialysis setup for discrete sampling. The probe (a) is perfused at a ﬁxed low ﬂow rate, and dialysate is collected into a
microvial (b) at the probe outlet. Right: shows the microvial when connected to the probe outlet holder. B. Photograph of combined needle
electrode based on a 27G hypodermic needle and schematic cross-section of the needle tip, showing the layers that make up the biosensor: (i) m-PD
exclusion layer, (ii) substrate oxidase (SOx) entrapped in a hydrogel, and (iii) diﬀusion limiting polyurethane outer ﬁlm. C. Exploded view of
custom-made microﬂuidic device for continuous monitoring of dialysate, showing the multicomponent system. The microﬂuidic chip (e) connects to
the probe outlet holder (c) in place of a microvial. The outlet holder needle enters the microvial rubber insert (d) at the inlet of the microﬂuidic chip.
Glucose and lactate needle biosensors ( f) are housed in custom-made electrode holders (g) that screw into the microﬂuidic chip, placing the
biosensors in the middle of the microﬂuidic channel and providing a good seal between the holder and the microﬂuidic device. (h) shows a
photograph of an electrode holder containing a needle biosensor. The black part at the base of the holder is made of soft, compressible plastic to
ensure the holder makes a good seal with the microﬂuidic chip. D. The L-shaped design provides a tidy and compact overall system.
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■ EXPERIMENTAL SECTION
Reagents. Glucose oxidase (GOx) from Aspergillus niger
and lactate oxidase (LOx) from Aerococcus viridians were
purchased from Sekisui Diagnostics. Polyurethane (Texin 985)
was obtained from Bayer. Other reagents were obtained from
Sigma-Aldrich.
Electrode Fabrication. The biosensors used in this work
are based on combined needle electrodes.20,36 Brieﬂy, a 50 μm
diameter polytetraﬂuoroethylene (PTFE) insulated platinum/
iridium (90%:10%) wire (Advent Research Materials, UK) and
a 50 μm polyester insulated silver wire were threaded through a
27G hypodermic needle. The insulation layer was removed
from the ends of the wires using a small ﬂame, to expose the
metal. The ends of the two wires were each connected to an
electrical wire using conductive silver epoxy glue (RS
Components, UK). Epoxy resin (Robnor resins, CY1301 and
HY1300) was used to ﬁll the needle and to secure the wires in
place. Once the epoxy resin was cured, the sharp tip of the
needle was abraded using sandpaper (Buehler, UK), to just
above the bevel of the needle, to create silver and platinum disc
electrodes. The blunt needle was then polished sequentially
with alumina slurries (1, 0.3, and 0.05 μm). Finally, in order to
create the Ag|AgCl reference electrode, the tip of the needle
was dipped into a potassium dichromate reference solution
(BASi, US) for 3 s, and then into a solution of diluted 37%
hydrochloric acid for 20 s, to remove the oxide layer from the
working and auxiliary electrodes. Cyclic voltammetry was used
to assess the working electrode surface.
Biosensor Fabrication. All biosensors were controlled
using in-house potentiostats and a PowerLab 8/35, controlled
by LabChart Pro (ADInstruments). Glucose and lactate
biosensors were fabricated in several layers, as shown in Figure
1-B. Layer i: The working electrode was ﬁrst coated with poly
m-phenylenediamine (m-PD) using electropolymerization, to
screen out potential interferences. Brieﬂy, the combined needle
electrode was placed in a 100 mM solution of m-phenylenedi-
amine in 0.01 M PBS at pH 7.4. The potential was held at 0 V
for 20 s, 0.7 V for 20 min for electropolymerization to occur,
and then 0 V for 5 min. The electrode was gently rinsed with
deionized water, and cyclic voltammetry was used to verify that
the working electrode had been successfully coated. Layer ii:
After successful electropolymerization of the screening layer,
the electrodes were dipped into the enzyme solution (60 mg/
mL LOx or GOx, 30 mg/mL bovine serum albumin, 60 mg/mL
poly(ethylene glycol) diglycidyl ether, and 2% v/v glycerol in
0.01 M PBS, adapted from the method described by Vasylieva
et al.37,38). The needles were placed in an oven at 55 °C for 2 h.
Layer iii: Following enzyme immobilization, biosensors were
also coated with a polyurethane ﬁlm in order to extend their
dynamic range to include the higher lactate levels possible in
exercising tissue and to minimize the eﬀect of any ﬂow
variations, which could occur in a ﬂow-cell, on biosensor
response.
Fabrication of Microﬂuidic Platform. Two diﬀerent 3D
printers were used for printing of the microﬂuidic platform.
The microﬂuidic chip was fabricated using a 3D printer
ULTRA 3SP. This machine provides 100 μm resolution in the
X- and Y-axis and between 25 and 100 μm resolution in the Z-
axis, depending on the parameters set. However, the true
resolution of the printer is given by the voxel dimension and
the material employed during fabrication. Throughout the
development of this work, the “ABS 3SP White” resist was used
for printing of the microﬂuidic chip. ABS 3SP White allows
printing of dimensionally and mechanically stable components,
although due to shrinkage of the resist in the printing process
smaller dimensions than those speciﬁed in the design of the
microﬂuidic channel were observed. In general, a tolerance of
about 100 μm needs to be considered during the design of the
components. The microﬂuidic platform was designed with an
L-shape, in which the inner microﬂuidic channel incorporates a
90° bend (Figure S1-A). As the microﬂuidic chip needs to
integrate two separate needle biosensors, one for glucose and
the other for lactate sensing, it was decided to insert the two
needles into the microﬂuidic channel through two round
openings printed on the top wall of the microchannel (Figure
S1-C). This conﬁguration ensures a tidy and compact
packaging of the overall platform, as shown in Figure 1-j.
However, it limits the minimum microchannel width that is
achievable, as it has to ﬁt the 27G needle (Ø = ca. 413 μm)
biosensors. Three diﬀerent sizes of microﬂuidic channels were
printed and tested, which had diﬀerent height and width
dimensions, these were as follows: (1) 520 × 520 μm, (2) 750
× 550 μm, and (3) 1000 × 550 μm. Moreover, taking into
account the material shrinkage, for channel (1) two slightly
wider microﬂuidic chambers were designed at the two needle
biosensor insertion locations (Figure S1-B) to avoid issues
during placement of the biosensors.
Printing of the needle holders was performed using the
Objet260 Connex 3D printer. The main advantage of using this
printer compared to the ULTRA 3SP is the possibility to print
rigid and soft material simultaneously on the same component.
For instance, VeroWhitePlus (RGD835) and TangoBlack
(FLX973) were employed for the printing of the rigid and
soft parts, respectively. To ﬁx the position of the needle
biosensor inside the holder two grub screws M2.5 were also
used. The rubbery part of the holder has a truncated cone shape
to guarantee ﬂuidic sealing and to avoid incorrect positioning of
the biosensors inside the microﬂuidic channel. In fact, initial
attempts using a cylindrical shape rubber part lead to incorrect
mounting of the biosensor holder into the microﬂuidic chip due
to XY expansion of the rubber when compressed.
Calibration and Characterization Studies. Glucose and
lactate biosensors were both held at a constant potential of +0.7
V vs Ag|AgCl. The biosensors were calibrated inside the
microﬂuidic chip using a calibration board, consisting of two
LabSmith 20 μL programmable syringe pumps, one containing
T1 perfusion solution and one containing a glucose/lactate
standard. By mixing the ﬂows, a multipoint calibration was
carried out by varying the relative ﬂow rates of the two pumps,
while keeping the overall ﬂow rate constant at 1 μL/min. This
system was also used to measure the time response of the
biosensors in the microﬂuidic chip, by switching between the
two solutions and measuring the time taken for the sensors to
reach a steady current. In vitro microdialysis experiments were
conducted using an expired microdialysis probe (CMA70,
MDialysis, 10 mm membrane length, 20 kDa molecular-weight
cutoﬀ), perfused with T1 solution (2.3 mM calcium chloride,
147 mM sodium chloride, and 4 mM potassium chloride) at 1
μL/min using a microdialysis pump (CMA107, MDialysis).
Cycling Protocol. For in vivo microdialysis experiments, all
procedures were approved by the local ethics committee
(NRES 10/H0808/124, protocol CRO1608), and probes were
inserted percutaneously by a qualiﬁed clinician. The skin was
cleaned with alcohol wipes, and an anesthetic cream (EMLA,
APP Pharmaceuticals) was applied to the skin 45 min prior to
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probe insertion. An ice pack was also placed on the skin 5 min
before probe insertion, to further numb the area. A sterile
CMA63 microdialysis probe (Mdialysis, 10 mm membrane
length, 20 kDa molecular-weight cutoﬀ) was inserted
subcutaneously, using the tunnelling needle and introducer
supplied, and secured in place with 3M single coated
conformable incise medical tape. The probe was perfused
with sterile T1 perfusion solution (MDialysis) at 1 μL/min
using a microdialysis pump (CMA107, MDialysis). Prior to
beginning exercise, baseline dialysate levels of glucose and
lactate were measured. The cycling protocol consisted of 3
levels of increasing intensity, followed by a 1 min sprint, and
ﬁnally a warm-down phase, as shown in Figure 4-A. Dialysate
glucose and lactate levels were also recorded during the
recovery phase immediately after exercise.
Cycling trials were performed using a Wattbike (Wattbike,
UK), that allows recording of pedal cadence (rpm) and heart
rate using a wireless chest belt (Sunto dual chest belt). Data
was despiked,39 and the time delay between the microdialysis
probe and the analysis system removed. Current measurements
were converted into concentration values using pre-experiment
calibrations.
■ RESULTS AND DISCUSSION
3D Printed Microﬂuidic Device. The design of the 3D
printed microﬂuidic device was driven by the need to make a
reliable and simple connection between the microﬂuidic chip
and the commercially available microdialysis probe through the
use of the probe outlet holder (Figure 1-C item c). This
simpliﬁes the overall device architecture, as no extra connection
tubing and adaptors are needed, additionally decreasing the
overall dead volume of the system.
The design of the microﬂuidic device was inspired by the
conﬁguration used in the standard microdialysis setup (Figure
1-A), in which the microﬂuidic device slots into the probe
outlet holder and replaces the microvial, as shown in Figure 1-
D. To achieve this, the microﬂuidic chip (Figure 1-C item e)
was designed and printed with a unique L-shape, the vertical
arm for connection purposes and the horizontal arm for
integration of the two needle biosensors. The vertical arm of
the chip presents similar geometry to the microvial. For
instance, the microﬂuidic inlet port was printed to incorporate
the rubber insert (Figure 1-C item d) from the microvial, so as
to take advantage of the easy and leak-free connection port.
Moreover, this design oﬀers ﬂexibility for the device to be used
in a diverse range of microdialysis applications, as it can be used
with all clinical microdialysis probes, since they have the same
type of outlet holder.
With regard to the horizontal section of the microﬂuidic
device, a major challenge was to incorporate and secure the
biosensors in the correct position inside the microﬂuidic
channel, preventing any leaks. Initially, attempts were made to
achieve this by threading the needle electrode through a
commercially available 1/32″ one-piece ﬁtting (2-56 UNC) and
using this to secure the electrode in place inside the
microﬂuidic chip.30 Using this approach, the device dimensions
were determined by the size of the ﬁttings and as such were
relatively large (over 1 mm). However, integrating the
biosensor in this way did not provide a good seal with the
microﬂuidic chip, causing leaks to occur. Erkal et al. showed
that electrodes could be successfully integrated with 3D printed
microﬂuidic devices using commercially available ﬁttings;
however, due to the small size of our sensor, a 1/32″ ﬁtting
was required. These threads were too small (2-56 UNC) to be
printed and a thread tapping tool (M2.5) was used instead.
Unfortunately this approach did not provide a satisfactory seal
or good reproducibility. To overcome the issue of the previous
method, custom-made electrode holders (Figure 1-C parts g
and h) were also designed and 3D printed, which allow better
control over the electrode placement inside the microﬂuidic
channel.
The electrode holder was printed using the Objet260
Connex 3D printer, capable of printing both hard and soft
plastics simultaneously on the same component. This enabled
the bottom part of the holder to be printed using a soft and
compressible plastic, ensuring a good seal between the holder
and the microﬂuidic device, preventing potential leaks. The
holders were designed so that the needle tip protruded from
the end and the needle was secured in place using two grub
screws. The needle position inside the holder could be varied
depending on the length of the needle, as this can change after
repeated polishing of the electrode (see supporting video 1).
This ensures that the needle tip is at a ﬁxed distance from the
end of the holder and hence in the correct position inside the
microﬂuidic channel. The microﬂuidic platform was designed
so that the holder could be guided into position; two pegs on
the sides of the electrode holder inserted into guiding slots and
locked into place, positioning the needle tip precisely inside the
channel (see supporting video 2). Moreover, to facilitate the
positioning of the electrode inside the microchannel an
additional cross-sectional cut-out of the microﬂuidic device
was printed. Using the cut-out component it was possible to
visualize the electrode inside the channel under a microscope
and to precisely secure the sensors inside the holders so that
the tip of the biosensor was at the desired height inside the
microchannel (Figure S2).
The use of 3D printing for fabrication of the device enabled a
modular approach to be adopted, designing separate parts to be
integrated together. Using this method each part of the device
could be designed and optimized iteratively to meet its own
individual requirements.
Biosensor Characterization Inside 3D Printed Micro-
ﬂuidic Chip. To investigate the eﬀect of the microﬂuidic
channel dimensions on the response time of the sensors, three
diﬀerent channel sizes were tested, as described in the
Experimental Section. Figure 2-B shows the normalized current
response of a glucose biosensor to a step change from 0 to 2
mM at 1 μL/min for the diﬀerent channel sizes. In each case
the sensor was positioned in the middle of the channel. Cross
sections of each channel were measured using a microscope to
determine the actual dimensions of each of the channels. The
dimensions speciﬁed in the table in Figure 2-B refer to the
measured dimensions.
Both glucose and lactate biosensors without the polyurethane
(PU) outer ﬁlm are fast responding (for a step change in well-
stirred beaker T90 glucose = 6.6 ± 3.9 s (n = 24), lactate = 5.1 ±
2.6 s (n = 30), data not shown). Addition of the PU ﬁlm to
extend the dynamic range (necessary for lactate biosensor)
slows both sensors (as shown in Figure 2-A) and increases the
variability in response as the PU thickness is diﬃcult to control
(for a step change T90 glucose = 36.1 ± 19.6 s (n = 5), lactate =
22.8 ± 11.3 s (n = 21)). The same biosensor shows good
reproducibility. For example, the sensors in Figure 2-A have T90
glucose = 21.0 ± 0.6 s (n = 3) and lactate = 26.1 ± 1.4 s (n =
3). Laminar ﬂow inside the connection tubing and microﬂuidic
channel leads to broadening of the concentration change, due
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to Taylor dispersion.28 In Figure 2-B we show that the time
response of the sensor to a step change is reduced by
decreasing the channel cross-sectional area. The T90 values are
summarized in Table 1 and are generally inversely proportional
to cross-sectional area and hence proportional to linear ﬂow
rate. In the channel, glucose values are longer than lactate ones
because the glucose biosensor was second in line and hence
exposed to a greater channel volume. The fastest response time
was observed in channel 1; therefore, these dimensions were
chosen for the ﬁnal device.
The horizontal section of the microﬂuidic chip is similar to
the microﬂuidic device described by Erkal et al., which had an
internal volume of 3.90 μL. Our microﬂuidic chip is broadly
similar, but the internal volume up until the ﬁrst biosensor is
approximately 1.91 μL based on measured dimensions.
Metabolite levels in tissue vary between people and depend
on a person’s metabolism and ﬁtness during exercise, as well as
on the particular tissue being sampled.40 The system was
calibrated online from 0 to 10 mM, at 1 μL/min to verify that it
is capable of detecting physiologically relevant concentrations
of glucose and lactate levels in the dialysate. Figure 3 shows
typical current response vs concentration for the biosensors
when placed in the microﬂuidic device. These data indicate that
the biosensing system has good sensitivity to glucose and
lactate, with clear current changes corresponding to increasing
levels of substrate. The biosensors show a good dynamic range,
suitable for physiological monitoring. The fact that sensitivities
are similar for the glucose and lactate sensors (Figure 3) reﬂects
the mass-transport limiting eﬀects of the PU membrane.
As a further validation test, it was important to test the
microﬂuidic device with a microdialysis probe in vitro. To
mimic changes occurring in the tissue, the microdialysis probe
was placed in a well-stirred beaker and subjected to changes in
beaker lactate and glucose concentrations. The outlet holder of
the microdialysis probe was connected to the microﬂuidic
device, which continuously measured the glucose and lactate
levels of the dialysate.
As the biosensors are placed consecutively in the microﬂuidic
chip, there is a 2 min delay between the lactate and glucose
responses to the dialysate changes. There is also an additional
delay to take into account between the changes occurring at the
probe membrane and the analysis system due to the length of
outlet tubing. Taking both factors into consideration, the total
delay was found to be 13 min for the lactate biosensor, which
was placed ﬁrst in the direction of ﬂow and 15 min for the
glucose biosensor, which was placed second in the direction of
ﬂow. This delay is largely caused by the commercially available
probe outlet tubing and, therefore, could be reduced further
still if the extension on the probe outlet was shortened.
Nevertheless, the delay time of the microﬂuidic device
described here was substantially improved compared to our
PDMS-based microﬂuidic device, which had a lag time of 25
min using the same ﬂow rate (1 μL/min).
Online Subcutaneous Glucose and Lactate Measure-
ment during Cycling Trials. In a proof-of-concept study to
demonstrate the potential of this device for continuous
monitoring applications the 3D printed microﬂuidic chip,
housing glucose and lactate needle biosensors, was tested as a
wearable device for online measurement of subcutaneous
metabolite levels during cycling training in two cyclists.
Following probe insertion, the microﬂuidic device was
connected to the probe outlet holder and secured to the
lower back, as shown in Figure 4-A. The biosensors were
connected to an in-house wireless potentiostat, housed inside a
saddlebag attached to the bike seat. The wireless potentiostat
used was relatively large (10.5 × 6.0 × 5.0 cm L × W × H)
compared to the microﬂuidic device and is not yet small
enough to be integrated into a fully wearable system. Current
research within our groups is aimed at miniaturization of this
device.
A schematic of the cycling protocol is shown in Figure 4-B.
Baseline glucose and lactate levels were measured in the
dialysate, following probe insertion, prior to exercise. The
exercise phase consisted of three levels of increasing intensity,
followed by a short sprint and a period of warming down.
Finally, dialysate glucose and lactate levels were monitored
during the recovery period following exercise.
Figure 2. A. Normalized current response of a 50 μm disc glucose
(red) and lactate (green) biosensor in a stirred beaker to a 2 mM
concentration step (purple arrow). B. The graph shows the normalized
current for a glucose biosensor to a step change from 0 to 2 mM at 1
μL/min in three diﬀerent microﬂuidic channels. The measured
channel sizes are shown in the table inset. The response time
increases as the channel dimension increases.
Table 1. Eﬀect of Channel Size on Response Time
channel dimensions H × W (μm) glucose T90 (s) lactate T90 (s)
375 × 508 208 ± 6.5 194 ± 15
410 × 615 267 ± 7.7 227 ± 7.0
421 × 971 398 ± 12.8 286 ± 6.9
Figure 3. Typical calibration curves for 50 μm disc glucose and lactate
biosensors in the microﬂuidic device at 1 μL/min. Mean ± standard
deviation of measurement shown (n = 4). Points ﬁtted with the
Michaelis−Menten equation. Inset: Raw data for a typical 5-point
lactate calibration from 0 to 4 mM in 1 mM steps.
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Initial levels after probe insertion were variable due to the
trauma of insertion. Therefore, baseline levels were monitored
for at least 30 min to allow time for the tissue to stabilize
following probe insertion; typically this occurred 12 min after
insertion.21
Results obtained from one of the cyclists during the exercise
phase of the cycling protocol are presented in Figure 4-C,
together with data recorded using the exercise bicycle, showing
heart rate and rotations per minute (rpm), to quantify the
exercise intensity. Initially, during phases ii and iii the heart rate
signal was noisy as there was insuﬃcient sweat to ensure good
contact between the skin and the wireless chest belt electrodes.
Prior to starting exercise, baseline glucose and lactate levels in
the dialysate were 6.02 ± 1.08 mM and 1.81 ± 0.33 mM,
respectively (mean ± standard deviation over 30 s time period).
Measured subcutaneous glucose levels decreased with increas-
ing exercise intensity, and local levels were driven down further
still following exercise, even after 50 min of rest. In contrast,
lactate levels increased with increasing exercise intensity,
peaking immediately after the sprint, and gradually decreased
once cycling had stopped. After 50 min of resting, dialysate
glucose and lactate levels were 1.84 ± 0.05 mM and 1.67 ± 0.03
mM, respectively.
To guard against possible changes in probe recovery, a ratio
of the two metabolites was also calculated. The lactate/glucose
ratio increased with exercise and rose more steeply with
increasing cycling intensity. Interestingly, the lactate/glucose
ratio continued to increase considerably, even after exercise had
stopped.
An overview of the dialysate glucose and lactate levels and
the lactate/glucose ratio throughout the cycling protocol for
two cyclists is shown in Figure 4-D. The overall trends in
glucose and lactate levels are similar for the two cyclists,
although the absolute concentrations appear quite diﬀerent.
This variability could be caused by changes in probe recovery
or by diﬀerences in the ﬁtness levels of the cyclists. In principle,
level changes caused by diﬀerences in probe recovery would
have been removed using ratios of analyte concentrations, such
Figure 4. A. Photograph of microﬂuidic device to measure tissue glucose and lactate levels in dialysate during the cycling protocol. Dialysate ﬂowed
into the microﬂuidic chip, housing the glucose and lactate biosensors, which were connected to wireless potentiostats, secured onto the bike. B.
Experimental protocol. Tissue levels were monitored during an initial resting period (i), followed by cycling at 4 levels of increasing rpm (ii-v), a level
of warming down (vi), and a ﬁnal period of resting (vii). C. Dialysate glucose and lactate levels during the exercise phase of the cycling protocol. The
bottom graph shows the glucose (red) and lactate (green) levels, the middle graph (black) shows the lactate/glucose ratio, and the top graph shows
the rotations per minute (blue) and heart rate (purple) throughout the cycling protocol. Glucose and lactate traces have been despiked.39 The dotted
lines indicate the stages of varying cycling intensity: (ii) 55 rpm, (iii) 65 rpm, (iv) 75 rpm, (v) sprint, and (vi) 55 rpm. Data has been time-aligned,
taking into account the time delay of the system. D. Histograms showing mean dialysate levels for two diﬀerent cyclists during key points in cycling
protocol. Labels correspond to stages described in the experimental protocol: (i) baseline (ii) midway through warm up, (iii) midway through
medium intensity, (iv) midway through high intensity, (v) end of sprint, (vi) end of warm down, and (vii) after 50 min of recovery.
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as the lactate/glucose ratio.16 Such ratios are widely used for
monitoring in the injured human brain (lactate/pyruvate)41 and
in muscle (lactate/pyruvate and lactate/glucose),42 though this
needs to be further investigated for subcutaneous tissue.
Nevertheless, there are clear diﬀerences in the lactate/glucose
ratio trend for the two cyclists.
■ CONCLUSION
We have demonstrated the ﬁrst example of a 3D printed
microﬂuidic device with integrated removable biosensors that
joins directly to a clinical microdialysis probe for continuous
human monitoring applications. Here we have demonstrated its
capabilities as a wearable device for subcutaneous monitoring of
tissue glucose and lactate levels in cyclists during exercise. The
clear changes recorded in the local glucose and lactate levels
indicate that this device could have huge potential for
monitoring and evaluating athlete training eﬀectiveness in
real-time. Moreover, this miniaturized device also has potential
for clinical microdialysis applications, such as bedside
monitoring, as its wearable nature removes the need for long
connection tubing, which usually leads to long lag times. Due to
the dimensional control provided by 3D printing, it was
possible to design the microﬂuidic device so that it could easily
be integrated with commercially available microdialysis probes,
making it suitable for numerous potential applications. Future
work will focus on miniaturization of the wireless potentiostats
to enable integration of the electronics within the wearable
device. Due to the modular nature of the device, the platform
can be expanded to include monitoring of other clinically
relevant biomarkers, oﬀering promise in a wide range of clinical
and ﬁtness applications.
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